Evidence map›Paper›PMID 31356124›Full record

ArticlePharmaceutical biology2019

Rhodiosin and herbacetin in

Zoltán Péter Zomborszki, Norbert Kúsz, Dezső Csupor, Wieland Peschel

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Herbacetin as a novel therapeutic agent for pulmonary and renal fibrosis by targeting TGFBR2 for degradation.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  4. Determination of Potential Inhibitors againstCurrent pharmaceutical design · 2026
    Review
  5. Article
  6. Influence ofInternational journal of molecular sciences · 2024
    Article
  7. Identification of potential inhibitors againstJournal of enzyme inhibition and medicinal chemistry · 2024
    Article
  8. Review
  9. Article
  10. Antibiotics (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Review
  13. Review
  14. Flavonoids: A complementary approach to conventional therapy of COVID-19?Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2021
    Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zoltán Péter Zomborszkia Faculty of Pharmacy, Department of Pharmacognosy, University of Szeged , Szeged , Hungary.
Norbert Kúsza Faculty of Pharmacy, Department of Pharmacognosy, University of Szeged , Szeged , Hungary.
Dezső Csupora Faculty of Pharmacy, Department of Pharmacognosy, University of Szeged , Szeged , Hungary.
Wieland Peschelc European Medicines Agency , London , UK.
University of Szeged · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FlavonoidsMonosaccharidesPlant ExtractsPlant RootsQuality ControlRhizomeRhodiolaFlavonoidsherbacetinMonosaccharidesPlant ExtractsrhodiosinflavonoidHPLC

Identifiers

PMID31356124
PMCPMC6711108
OpenAlexW2964709325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.